BIIB
BIIB
NASDAQ · Biotechnology

Biogen Inc

S&P 500 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks
$197.95
+4.50 (+2.33%)
As of May 11, 9:36 PM ET ·
BIIB News3 articles
Biogen Lowers 2026 Profit View Despite Q1 Beat; Leqembi Sales Soar 74%
Biogen lowered its 2026 adjusted earnings outlook to $14.25-$15.25 per share after Q1 results topped estimates. Leqembi sales jumped 74% to $168M globally.
Earnings
Biogen Acquires Apellis in $5.6B Deal, Adding Eye and Kidney Drugs
Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.
Markets
Biogen to Acquire Apellis in $5.6B Deal, Adding Rare Disease Portfolio
Biogen has entered an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal provides Apellis shareholders $41 per share upfront, with potential additional payments based on sales performance of the eye drug Syfovre.
Markets